ArticleJournal of clinical immunology2023

A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.

Andras Nagy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.